CN108339008A - 一种丹酚制剂在抗脑缺血再灌注损伤药物中的应用 - Google Patents
一种丹酚制剂在抗脑缺血再灌注损伤药物中的应用 Download PDFInfo
- Publication number
- CN108339008A CN108339008A CN201710073256.9A CN201710073256A CN108339008A CN 108339008 A CN108339008 A CN 108339008A CN 201710073256 A CN201710073256 A CN 201710073256A CN 108339008 A CN108339008 A CN 108339008A
- Authority
- CN
- China
- Prior art keywords
- cerebral ischemia
- reperfusion injury
- ischemia reperfusion
- rat
- mcao
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 206010008118 cerebral infarction Diseases 0.000 title claims abstract description 33
- 201000006474 Brain Ischemia Diseases 0.000 title claims abstract description 27
- 206010008120 Cerebral ischaemia Diseases 0.000 title claims abstract description 27
- 206010063837 Reperfusion injury Diseases 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000008188 pellet Substances 0.000 title claims abstract description 8
- 210000004556 brain Anatomy 0.000 claims abstract description 10
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims abstract description 9
- 238000005516 engineering process Methods 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims abstract description 4
- 229960000715 nimodipine Drugs 0.000 claims abstract description 3
- 241000700159 Rattus Species 0.000 claims description 45
- 230000010410 reperfusion Effects 0.000 claims description 30
- 230000000302 ischemic effect Effects 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 8
- 206010008089 Cerebral artery occlusion Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims 7
- 230000001154 acute effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 9
- 238000004043 dyeing Methods 0.000 abstract description 6
- 102000004420 Creatine Kinase Human genes 0.000 abstract description 4
- 108010042126 Creatine kinase Proteins 0.000 abstract description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 abstract description 4
- 108010012715 Superoxide dismutase Proteins 0.000 abstract description 4
- 101710088194 Dehydrogenase Proteins 0.000 abstract description 3
- 206010014513 Embolism arterial Diseases 0.000 abstract description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 abstract description 3
- 206010008092 Cerebral artery thrombosis Diseases 0.000 abstract description 2
- 201000008247 brain infarction Diseases 0.000 abstract description 2
- 230000009537 cortical lesion Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 description 26
- 238000001727 in vivo Methods 0.000 description 20
- 238000000034 method Methods 0.000 description 9
- 230000002490 cerebral effect Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 210000000269 carotid artery external Anatomy 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000007971 neurological deficit Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 240000007164 Salvia officinalis Species 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- -1 LDH) Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 208000003906 hydrocephalus Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000022306 Cerebral injury Diseases 0.000 description 1
- 208000037823 Cerebral ischemia/reperfusion injury Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710073256.9A CN108339008A (zh) | 2017-01-25 | 2017-01-25 | 一种丹酚制剂在抗脑缺血再灌注损伤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710073256.9A CN108339008A (zh) | 2017-01-25 | 2017-01-25 | 一种丹酚制剂在抗脑缺血再灌注损伤药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108339008A true CN108339008A (zh) | 2018-07-31 |
Family
ID=62962034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710073256.9A Pending CN108339008A (zh) | 2017-01-25 | 2017-01-25 | 一种丹酚制剂在抗脑缺血再灌注损伤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108339008A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113827587A (zh) * | 2020-06-24 | 2021-12-24 | 中国医学科学院药物研究所 | 丹酚酸a在制备预防血栓性脑缺血的药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679811A (zh) * | 2005-02-04 | 2005-10-12 | 邢为藩 | 一种丹参提取物、其制备方法、药物制剂及检测方法 |
CN103301104A (zh) * | 2012-11-20 | 2013-09-18 | 蒋春红 | 丹酚酸a组合物用于制备挽救缺血半暗带药物的用途 |
CN104910112A (zh) * | 2015-04-28 | 2015-09-16 | 南京宸翔医药研究有限责任公司 | 一种高纯度的中药丹参有效成分丹酚酸b的制备方法、药物制剂及临床应用 |
-
2017
- 2017-01-25 CN CN201710073256.9A patent/CN108339008A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679811A (zh) * | 2005-02-04 | 2005-10-12 | 邢为藩 | 一种丹参提取物、其制备方法、药物制剂及检测方法 |
CN103301104A (zh) * | 2012-11-20 | 2013-09-18 | 蒋春红 | 丹酚酸a组合物用于制备挽救缺血半暗带药物的用途 |
CN104910112A (zh) * | 2015-04-28 | 2015-09-16 | 南京宸翔医药研究有限责任公司 | 一种高纯度的中药丹参有效成分丹酚酸b的制备方法、药物制剂及临床应用 |
Non-Patent Citations (4)
Title |
---|
任德成等: "总丹酚酸对脑缺血再灌注损伤的保护作用", 《中国药理学通报》 * |
吴俊芳等: "总丹酚酸对小鼠和大鼠脑缺血再灌注损伤的保护作用", 《药理实验与临床观察》 * |
商洪才等: "丹参酚酸A、B对大鼠局灶性脑缺血损伤保护效应比较", 《中药药理与临床》 * |
龚千锋: "《中药炮制学 新世纪第3版》", 31 January 2013, 中国中医药出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113827587A (zh) * | 2020-06-24 | 2021-12-24 | 中国医学科学院药物研究所 | 丹酚酸a在制备预防血栓性脑缺血的药物中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103816280B (zh) | 一种治疗心肌梗死的中药组合物及其应用 | |
JP2016540833A (ja) | 広金銭草総フラボノイドカプセル剤およびその製造方法、並びにその応用 | |
CN101780227B (zh) | 一种治疗中风急性期的中药组合物及其制备方法 | |
KR101478882B1 (ko) | 고사리삼 추출물을 함유하는 뇌졸중 및 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 | |
CN1314417C (zh) | 用于治疗中风和胸痹的中药制剂及其制备方法 | |
CN108339008A (zh) | 一种丹酚制剂在抗脑缺血再灌注损伤药物中的应用 | |
CN107744571B (zh) | 一种改善血管内皮功能障碍的药物组合物及其制备方法和用途 | |
CN104189781A (zh) | 一种治疗神经胶质瘤的中药组合物 | |
KR20210088775A (ko) | 한약재 혼합 추출물을 포함하는 신경병증성 통증의 예방 또는 치료용 약학적 조성물 | |
KR101359760B1 (ko) | 노루오줌 추출물을 함유하는 퇴행성 뇌질환 예방 및 치료용 약학적 조성물 | |
CN100382808C (zh) | 南葶苈子油在制备具有脑神经调节功能组合物中的应用 | |
CN110478450B (zh) | 一种治疗阿尔茨海默病的药物组合物及其应用 | |
KR100526404B1 (ko) | 황기 추출물을 포함하는 뇌허혈성 신경세포손상 방지용조성물 | |
CN116999486B (zh) | 一种治疗缺血性中风恢复期的壮药复方药物及其制备方法 | |
CN102526583B (zh) | 一种用于治疗老年性痴呆的中药组合物及其制法和用途 | |
CN103768349A (zh) | 四味大果木姜子制剂在制备治疗脑血管及相关疾病药物中的应用 | |
Eryilmaz | A 28-DAYS SUB-ACUTE TOXICITY STUDY IN SWISS ALBINO MICE TO ASSESS NEUROTOL PLUS (GLYCEROL AND MANNITOL IN COMBINATION) TOXICITY PROFILE | |
KR100526405B1 (ko) | 신경세포 보호용 매자나무 추출물 및 이를 포함하는뇌질환 예방 및 치료용 조성물 | |
CN101732442B (zh) | 含有荭草的组合物在制备治疗脑血管及相关疾病药物中的应用 | |
CN106913776A (zh) | 治疗脑血栓和/或脑溢血的中药组合物及其制备方法 | |
CN105535429A (zh) | 一种治疗帕金森病的中药及其制备方法 | |
CN105288131A (zh) | 一种治疗肾结核的中药汤剂及其制备方法 | |
CN1593574A (zh) | 治疗心脑血管疾病的中药制剂及其制备方法 | |
CN108653586A (zh) | 一种中药组合物在制备治疗帕金森病药物中的应用 | |
CN108379515A (zh) | 具有治疗心绞痛作用的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190711 Address after: 211100 4th Floor, No. 5 Qiande Road, Jiangning District, Nanjing City, Jiangsu Province Applicant after: NANJING CHENXIANG MEDICAL RESEARCH CO.,LTD. Address before: 211100 4th Floor, No. 5 Qiande Road, Jiangning District, Nanjing City, Jiangsu Province Applicant before: Xing Weifan |
|
TA01 | Transfer of patent application right | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180731 |
|
CI02 | Correction of invention patent application | ||
CI02 | Correction of invention patent application |
Correction item: deemed withdrawal of application for invention after its publication Correct: Revocation of invention patent application after publication is deemed to be withdrawn False: The invention patent application is deemed withdrawn after publication Number: 29-01 Volume: 38 |
|
RA01 | Restoration of patent right | ||
RA01 | Restoration of patent right |
Former decision: Deemed withdrawal after publication of patent application Former decision publication date: 20220719 |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Xing Weifan Document name: Amendment and Correction Notice |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180731 |